Scientific Letters
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: July 10, 2025
Accepted: August 1, 2025
Accepted: August 1, 2025
827
Views
488
Downloads
Authors
B-cell prolymphocytic leukemia (B-PLL) is a rare lymphoproliferative disorder characterized by splenomegaly, lymphocytosis, and poor prognosis. Treatment options are limited, with modest responses to chemo-immunotherapy. We present two elderly patients with B-PLL treated with Zanubrutinib, a second-generation BTK inhibitor, achieving good disease response and tolerance. Both had TP53 deletion/mutations and high-risk complex karyotype. They obtained partial remission with normalization of hematologic parameters and spleen size. Given the rarity of the disease, further studies are needed to define treatment strategies, but Zanubrutinib appears to be a promising drug in this rare orphan drug disease.
Downloads
Download data is not yet available.
Citations
References:
Catovsky D, Galetto J, Okos A, et al. Prolymphocytic leukaemia of B and T cell type. Lancet 1973; 2: 232–234.
Shvidel L, Shtalrid M, Bassous L, et al. B-Cell Prolymphocytic Leukemia: A Survey of 35 Patients Emphasizing Heterogeneity, Prognostic Factors and Evidence for a Group with an Indolent Course. Leukemia & Lymphoma 1999; 33: 169–179.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720–1748.
Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140: 1229–1253.
El Hussein S, Khoury JD, Medeiros LJ. B-prolymphocytic leukemia: Is it time to retire this entity? Annals of Diagnostic Pathology 2021; 54: 151790.
Chapiro E, Pramil E, Diop M, et al. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood 2019; blood.2019001187.
Lens D, J.J.C. De Schouwer P, Hamoudi RA, et al. p53 Abnormalities in B-Cell Prolymphocytic Leukemia. Blood 1997; 89: 2015–2023.
Mouhssine S, Maher N, Matti BF, et al. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms. IJMS 2024; 25: 3234.
Oka S, Ono K, Nohgawa M. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia. Invest New Drugs 2020; 38: 1598–1600.
Jain A, Khunger J, Prasad P, et al. An illustrative case of B-cell prolymphocytic leukemia. Blood Res 2020; 55: 181–184.
Salvi F, Miller MD, Grilli A, et al. A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly Patients. J American Geriatrics Society 2008; 56: 1926–1931.
Xing L, He Q, Xie L, et al. Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review. haematol 2021; 107: 1226–1228.
Ethics Approval
B-cell prolymphocytic leukemiaSupporting Agencies
BeiGeneHow to Cite
“Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies”. (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025061. doi:10.4084/MJHID.2025.061.
Copyright (c) 2025 Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
